Incyte Corporation INCY recently announced positive top-line results from the late-stage TRuE-AD3 study on Opzelura (ruxolitinib cream). TRuE-AD3 (NCT04921969) is a randomized, double-blind, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results